Analytical performance of a delayed-centrifugation blood collection tube for remote blood biomarker assessment
- 1University of Pittsburgh
Abstract
Current biobanking guidelines require in-person blood collection and immediate processing for Alzheimers disease (AD) biomarker assessment. We recently reported that the P100 blood collection tubes containing protease inhibitors improve protein biomarker stability over delayed centrifugation periods. However, whether this comparability extends beyond a small set of biomarkers to the broad panels enabled by high-plex platforms has not been established. Here, we performed a head-to-head comparison of 127 neurodegeneration-related biomarkers in paired P100 vs. standard ethylenediaminetetraacetic acid (EDTA) plasma samples from n = 43 community-dwelling older adult participants using the NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) proteomic technology. The NULISA assay demonstrated excellent technical reproducibility (intra- and inter-plate coefficients of variation [CVs] <10%). Biomarker levels in P100 and EDTA tubes were strongly correlated, with mean and median Spearman coefficients exceeding {rho} = 0.8. Six conventional AD biomarkers showed strong P100-EDTA correlations ({rho} > 0.8) with minimal mean differences and no significant proportional bias in Bland-Altman analysis, including plasma A{beta}42, GFAP, MAPT, NEFL, p-tau181, and p-tau231, while p-tau217 showed a P100-EDTA correlation of {rho} = 0.57. Two biomarker ratios (A{beta}42/A{beta}40 and p-tau217/A{beta}42) also showed minimal bias with no proportional bias detected. Receiver operating characteristic analysis using amyloid status, assessed with positron emission tomography in a subset of participants, showed comparable classification performance between the two tube types, with classification concordance up to 92% and no significant DeLong differences for most (80%) biomarkers. These findings indicate that, on the NULISA platform, P100 tubes yield analytical and classification performance comparable to conventional EDTA tubes, supporting their use for blood-based neurodegeneration biomarker research where immediate sample processing is not feasible.
Related
- Delayed-centrifugation blood collection tube for remote blood biomarker assessment
- Performance Assessment of Centrifugation-Based Hematocrit Testing in Primary Care Units: Evidence from Seventy-Two Proficiency Testing Datasets over Eight Years
- Biomarker Convert: a novel approach to transform plasma pTau217 results across immunoassay and mass spectrometry analytical platforms
- Analytical Agreement and Diagnostic Performance of a Commercial Point-of-Care Lipid Testing System for Lipid Profile and Atherogenic Ratios
- Plasma biomarker strategies to reduce diagnostic uncertainty in p-tau217–based assessment of CSF amyloid positivity in secondary-care patients with MCI
BibTeX
@misc{lee2026analytical,
title = {{Analytical performance of a delayed-centrifugation blood collection tube for remote blood biomarker assessment}},
author = {Y.-R. Lee and X. Zeng and M. F. Farinas and B. J. Lopresti and R. F. Habte and K. A. Wilckens and T. K. Karikari},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.05.26364780},
url = {https://www.medrxiv.org/content/10.64898/2026.10.05.26364780v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Analytical performance of a delayed-centrifugation blood collection tube for remote blood biomarker assessment
AU - Y.-R. Lee
AU - X. Zeng
AU - M. F. Farinas
AU - B. J. Lopresti
AU - R. F. Habte
AU - K. A. Wilckens
AU - T. K. Karikari
PY - 2026
DA - 2026/10/05
PB - medRxiv
DO - 10.64898/2026.10.05.26364780
UR - https://www.medrxiv.org/content/10.64898/2026.10.05.26364780v1
AB - Current biobanking guidelines require in-person blood collection and immediate processing for Alzheimers disease (AD) biomarker assessment. We recently reported that the P100 blood collection tubes containing protease inhibitors improve protein biomarker stability over delayed centrifugation periods. However, whether this comparability extends beyond a small set of biomarkers to the broad panels enabled by high-plex platforms has not been established. Here, we performed a head-to-head comparison of 127 neurodegeneration-related biomarkers in paired P100 vs. standard ethylenediaminetetraacetic acid (EDTA) plasma samples from n = 43 community-dwelling older adult participants using the NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) proteomic technology. The NULISA assay demonstrated excellent technical reproducibility (intra- and inter-plate coefficients of variation [CVs] <10%). Biomarker levels in P100 and EDTA tubes were strongly correlated, with mean and median Spearman coefficients exceeding {rho} = 0.8. Six conventional AD biomarkers showed strong P100-EDTA correlations ({rho} > 0.8) with minimal mean differences and no significant proportional bias in Bland-Altman analysis, including plasma A{beta}42, GFAP, MAPT, NEFL, p-tau181, and p-tau231, while p-tau217 showed a P100-EDTA correlation of {rho} = 0.57. Two biomarker ratios (A{beta}42/A{beta}40 and p-tau217/A{beta}42) also showed minimal bias with no proportional bias detected. Receiver operating characteristic analysis using amyloid status, assessed with positron emission tomography in a subset of participants, showed comparable classification performance between the two tube types, with classification concordance up to 92% and no significant DeLong differences for most (80%) biomarkers. These findings indicate that, on the NULISA platform, P100 tubes yield analytical and classification performance comparable to conventional EDTA tubes, supporting their use for blood-based neurodegeneration biomarker research where immediate sample processing is not feasible.
ER -